Stocks TradingCharts.com

stocks prices, charts & quotes

Free Stock Prices, Charts & Stock Price Quotes

Search
Symbol Search Browse Symbols My Charts Menu
QUICK QUOTE
QUICK CHART
F.A.Questions Suggestion Box Advertising Info Commodity Charts Forex Markets

Stocks & Financial News

Breaking financial news 24/7 courtesy of TradingCharts.com Inc. / TFC Commodity Charts

DGAP-News: Byondis B.V.: Byondis Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

Jan 11, 2021 (EQS Group AG via COMTEX) --

DGAP-News: Byondis B.V. / Key word(s): Conference
Byondis B.V.: Byondis Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

11.01.2021 / 15:00
The issuer is solely responsible for the content of this announcement.


Byondis Announces Upcoming Presentation at J.P. Morgan Healthcare Conference

Presentation and webcast to take place at: 07:30 AM EST on January 14

Nijmegen, The Netherlands - 11 January 2021 - Byondis, a clinical-stage biopharmaceutical company today announced that its Chief Executive Officer, Marco Timmers, Ph.D., will present at the J.P. Morgan Healthcare Conference at 07:30 AM EST / 01:30 PM Central European Time (CET) on Thursday, January 14, 2021. A link to the live audio webcast of this presentation will be available on the Events Calendar of www.byondis.com. A replay will also be available on the Byondis website following the presentation.

About Byondis
Driven to improve patients' lives, Byondis is an independent clinical-stage biopharmaceutical company creating innovative precision medicines targeting intractable cancers and autoimmune diseases. The company is developing new biological entities (NBEs) and new chemical entities (NCEs) and differentiates itself from other biopharmaceutical companies by its proprietary molecular concepts, such as its linker-drug (LD) and site-specific conjugation technologies to generate antibody-drug conjugates (ADCs).

Byondis' broad development portfolio comprises preclinical and early- and late-stage clinical programs, including the anti-HER2 ADC [vic-]trastuzumab duocarmazine (SYD985, Phase III). The company has a dedicated team of more than 350 staff including highly educated scientists and skilled technicians working in its state-of-the-art R&D and GMP manufacturing facilities in Nijmegen, the Netherlands. Byondis collaborates with global biotechnology and pharmaceutical companies and national and international academic research institutions. For more information visit www.byondis.com.

- ENDS -

Contacts

Byondis
Corina Ramers-Verhoeven
Vice President, Corporate Communications
P: +31 (0)24 679 44 44
M: +31 (0)6 10 95 47 70
Corina.Ramers-Verhoeven@byondis.com

Public Eyes Healthcare Communications
Yvonne Massar
+31 (0) 6 55 13 48 60
yvonne@publiceyes.nl



11.01.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


1159637 11.01.2021

fncls.ssp?fn=show_t_gif&application_id=1159637&application_name=news&site_id=comtex comtex tracking

Do not sell my personal information

Copyright © 2021. All market data is provided by Barchart Solutions. Information is provided "as is" and solely for informational purposes, not for trading purposes or advice. To see all exchange delays and terms of use, please see disclaimer.